Andrew Cittadine - 30 Sep 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role: Chief Operating Officer
Signature: /s/ Quan Vu, Attorney-in-fact
Issuer symbol: MNPR
Transactions as of: 30 Sep 2025
Net transactions value: -$154,846
Form type: 4
Filing time: 02 Oct 2025, 15:04:36 UTC
Previous filing: 02 Jul 2025
Next filing: 08 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cittadine Andrew	Chief Operating Officer	1000 SKOKIE BLVD SUITE 350, WILMETTE	/s/ Quan Vu, Attorney-in-fact	02 Oct 2025	0001863624

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MNPR	Common Stock	Options Exercise		+4,327	+9.4%		50,185	30 Sep 2025	Direct	F1
transaction	MNPR	Common Stock	Tax liability	$154,846	-1,896	-3.8%	$81.67	48,289	30 Sep 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MNPR	Restricted Stock Units	Options Exercise	$0	-4,327	-10%	$0.000000	38,674	30 Sep 2025	Common Stock	4,327		Direct	F1, F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares acquired on vesting and settlement of restricted stock units.
F2	Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3	On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F4	On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5	On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.